Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients

J Pediatr Hematol Oncol. 2007 Dec;29(12):815-21. doi: 10.1097/MPH.0b013e3181581506.

Abstract

Defective apoptosis signaling by the Fas pathway has carcinogenic implications. We analyzed 123 pediatric patients with osteosarcoma for Fas single nucleotide polymorphisms: 2 of the promoter region (-1377 G>A and -670 A>G) and 2 of the coding region (exon 3 18272 A>G and exon 7 22628 C>T). As a comparison group, we used 510 adults without a history of cancer. We found an increased risk of osteosarcoma associated with the heterozygous genotype Fas exon 3 AG (genotype frequency 19.5% in cases vs. 12.0% in controls, P=0.028; adjusted odds ratio=1.6, 95% confidence interval=0.9-2.7], and this association was more pronounced in non-Hispanic whites (20.6% in cases vs. 10.1% in controls, P=0.014; adjusted odds ratio=2.3, 95% confidence interval=1.2-4.6). Additionally, the frequency of the variant allele (exon 3 G) was significantly higher in cases than in controls for both the entire group and non-Hispanic whites (P=0.046 and P=0.030, respectively). We found no significant association between osteosarcoma risk and the other Fas polymorphisms. This study suggests an association between the Fas exon 3 A>G polymorphism and osteosarcoma risk; however, further study is needed with pediatric controls and a larger sample size.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bone Neoplasms / genetics*
  • Child
  • Exons
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Osteosarcoma / genetics*
  • Polymorphism, Genetic*
  • Polymorphism, Single Nucleotide*
  • Promoter Regions, Genetic
  • Reference Values
  • fas Receptor / genetics*

Substances

  • FAS protein, human
  • fas Receptor